Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer or Increased MET or AXL Activity

Inclusion criteria: The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.

Sponsor/Collaborator: Memorial Sloan Kettering Cancer Center|Exelixis

Contact and Locations:
Study contact: Alexander Drilon, MD
Phone Number: 646-888-4206

Mechanism of action: Cabozantinib is an oral medicine that inhibits of RET, ROS1, NTRK, MET, and AXL. In many of these cases, increased activation of the mesenchymal-epithelial transition (cMet) pathway appears to be a bypass signaling mechanism that allows cancer cells to circumvent the selective pressure from RET inhibitors.

Phases: Phase 2

NCT Number: NCT01639508

Status: Recruiting

Back to clinical trials list